Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

NCT04214951 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04214951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04214951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2020
Completion date
December 31, 2022
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corticosteroid-resistant or relapsed itp